GILD Financial Facts
Cost of goods sold: 1.13BNet loss attributable to noncontrolling interest: -5M
See Full Income Statement
Long-term marketable securities: 19.35B
Other accrued liabilities: 3.48B
See Full Balance Sheet
Gilead Sciences Inc. (GILD) Earnings
|
Expand Research on GILD
| Next EPS Date | 10/22/26 | EPS Growth Rate | -14.2% |
|---|---|---|---|
| Average EPS % Beat Rate | +7.5% | Revenue Growth Rate | -0.3% |
| Average % Move 1-Wk after EPS | +1.8% | Normal Earnings Time | After Close |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
10/22/26  |
Q326 | N/A | $2.12 | N/A | N/A | $7.78B | = | N/A | N/A | ||
| 8/4/26 |
Q226 | -$6.75 | -$7.31 | +$0.56 | $7.8B | $7.4B | = |  | | Details | |
| 5/7/26 | Q126 | $2.03 | $1.90 | +$0.13 | $7B | $6.91B | = | | | Details | |
| 4/23/26 |
Q126 | N/A | $1.90 | N/A | N/A | $6.91B | = | N/A | N/A | ||
| 2/10/26 | Q425 | $1.86 | $1.85 | +$0.01 | $7.93B | $7.68B | = | | | Details | |
| 10/30/25 | Q325 | $2.47 | $2.15 | +$0.32 | $7.8B | $7.45B | = | | | Details | |
| 8/7/25 | Q225 | $2.01 | $1.96 | +$0.05 | $7.1B | $6.97B | = | | | Details | |
| 4/24/25 | Q125 | $1.81 | $1.77 | +$0.04 | $6.67B | $6.78B | = | | | Details |
